# CVS HEALTH Corp: Form 10-Q for the period ended Sep 30, 2009

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2009-11-05
- Accepted by EDGAR: Nov 5, 2009, 14:11 ET
- Period: 2009-09-30
- Accession: 0001193125-09-225277
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000119312509225277/d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000119312509225277/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2009-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2009-07-01 to 2009-09-30 | $24.64bn | us-gaap:Revenues |
| Revenue | 9 months, 2009-01-01 to 2009-09-30 | $72.91bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2009-07-01 to 2009-09-30 | $19.63bn | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2009-01-01 to 2009-09-30 | $58.09bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2009-07-01 to 2009-09-30 | $5.01bn | us-gaap:GrossProfit |
| Gross profit | 9 months, 2009-01-01 to 2009-09-30 | $14.81bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2009-07-01 to 2009-09-30 | $1.57bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2009-01-01 to 2009-09-30 | $4.54bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2009-07-01 to 2009-09-30 | $420.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2009-01-01 to 2009-09-30 | $1.49bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2009-07-01 to 2009-09-30 | $1.02bn | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2009-01-01 to 2009-09-30 | $2.65bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2009-07-01 to 2009-09-30 | $0.71 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2009-01-01 to 2009-09-30 | $1.81 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2009-07-01 to 2009-09-30 | $0.71 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2009-01-01 to 2009-09-30 | $1.83 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2009-07-01 to 2009-09-30 | 1,444,900,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2009-01-01 to 2009-09-30 | 1,461,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2009-01-01 to 2009-09-30 | $2.23bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2009-01-01 to 2009-09-30 | $1.75bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2009-01-01 to 2009-09-30 | $330.8m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months, 2009-01-01 to 2009-09-30 | $1.54bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2009-09-30 | $1.13bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2009-09-30 | $17.40bn | us-gaap:AssetsCurrent |
| Total assets | at 2009-09-30 | $61.88bn | us-gaap:Assets |
| Current liabilities | at 2009-09-30 | $12.70bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2009-09-30 | $26.20bn | us-gaap:Liabilities |
| Long-term debt | at 2009-09-30 | $8.76bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2009-09-30 | $2.10bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2009-09-30 | $1.10bn | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2009-09-30 | $35.67bn | us-gaap:StockholdersEquity |

## Market risk

As filed, 292 characters.

As of September 30, 2009, the Company had no derivative financial instruments or derivative commodity instruments in place and believes that its exposure to market risk associated with other financial instruments, principally interest rate risk inherent in its debt portfolio is not material.

## Controls and procedures

As filed, 8,621 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of September 30, 2009, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 that occurred during the third quarter ended September 30, 2009 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Part II Item 1

### Legal Proceedings

See Item 3 of Part I to our Annual Report on Form 10-K for the fiscal year ending December 31, 2008 for disclosure relating to material pending legal proceedings. Set forth below is a summary of material developments involving a material pending legal proceeding that occurred subsequent to the filing of our 10-K.

1\. Caremark’s subsidiary Caremark, Inc. (now known as Caremark, L.L.C.) is a defendant in a *qui tam* lawsuit initially filed by a relator on behalf of various state and federal government agencies in Texas federal court in 1999. The case was unsealed in May 2005. The case seeks monetary damages and alleges that Caremark’s processing of Medicaid and certain other government claims on behalf of its clients (which allegedly resulted in underpayments from our clients to the applicable government agencies) violates applicable federal or state False Claims Acts and fraud statutes. The United States and the States of Texas, Tennessee, Florida, Arkansas, Louisiana and California intervened in the lawsuit, but Tennessee and Florida withdrew from the lawsuit in August 2006 and May 2007, respectively. The parties previously filed cross motions for partial summary judgment, and in August 2008, the court granted several of Caremark’s motions and denied the motions filed by the plaintiffs. The court’s recent rulings are favorable to Caremark and substantially limit the ability of the plaintiffs to assert False Claims Act allegations or statutory or common law theories of recovery based on Caremark’s processing of Medicaid and other government reimbursement requests. The state plaintiffs and the relator filed motions asking the court to reconsider its rulings, and these motions were recently denied. The United States is seeking an appeal of the court’s rulings. In April 2009, the State of Texas filed a purported civil enforcement action against Caremark for injunctive relief, damages and civil penalties in Travis County, Texas alleging that Caremark violated the Texas Medicaid Fraud Prevention Act and other state laws based on our processing of Texas Medicaid claims on behalf of PBM clients. The claims and issues raised in this lawsuit are related to the claims and issues pending in the federal *qui tam* lawsuit described above.

In December 2007, the Company received a document subpoena from the Office of Inspector General, United States Department of Health and Human Services (“OIG”), requesting information relating to the processing of Medicaid and other government agency claims on an adjudication platform of AdvancePCS (acquired by Caremark in 2004 and now known as CaremarkPCS, L.L.C.). The Company has initiated discussions with the OIG and with the U.S. Department of Justice concerning our government claims processing activities on the two adjudication platforms used by AdvancePCS and one adjudication platform used by PharmaCare. The Company is also cooperating with the requests for information contained in the document subpoena by producing responsive documents on a rolling basis. The Company cannot predict with certainty the timing, outcome or consequence of any review of such information.

In October 2009, the Company received two civil investigative demands from the Office of the Attorney General of the State of Texas requesting information relating to the processing of Medicaid and other government agency claims. The civil investigative demands are substantively identical and state that the Office of the Attorney General of the State of Texas is investigating allegations currently pending under seal relating to two adjudication platforms of AdvancePCS. The Company intends to cooperate with the requests for information contained in these civil investigative demands. The Company cannot predict with certainty the timing, outcome or consequence of any review of such information.

2\. Beginning in November 2008, the Company received and has been responding to several subpoenas from the Drug Enforcement Administration (“DEA”), Los Angeles Field Division, requesting sales data and other information regarding the Company’s distribution of products containing pseudoephedrine (“PSE”) at certain retail pharmacies and from one California distribution center. In September 2009, the United States Attorney’s Office for the Central District of California (“USAO”)

### Part II Item 1

### Legal Proceedings

and the DEA commenced discussions with the Company regarding whether, in late 2007 and 2008, the Company distributed PSE in violation of the Controlled Substances Act. Violations of the Controlled Substances Act could result in the imposition of civil and/or criminal penalties against the Company. In addition, the DEA has issued an order to show cause against certain retail pharmacies which could result in administrative action against the Company’s DEA registrations for these facilities. The DEA has informed the Company that it also intends to issue a similar order to show cause relating to the Company’s La Habra, California distribution center. Discussions are underway to resolve these matters, but whether an agreement can be reached and on what terms are uncertain.

3\. In August 2009, the Company was notified by the Federal Trade Commission (the “FTC”) that it is conducting a non-public investigation under the Federal Trade Commission Act into certain of the Company’s business practices. The Company is cooperating in the FTC’s investigation and is voluntarily producing documents and other information on a rolling basis as requested by the FTC. The Company is not able to predict with certainty the timing, outcome or consequence of the investigation. However, it remains confident that its business practices and service offerings (which are designed to reduce healthcare costs and expand consumer choice) are being conducted in compliance with the antitrust laws.

### Part II Item 2

### Unregistered Sales of Equity Securities and Use of Proceeds

(c) Stock Repurchases

The following table presents the total number of shares purchased during the third quarter of 2009, the average price paid per share, the number of shares that were purchased as part of a publicly announced tender offer and a separate, subsequent repurchase program, and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the $2.0 billion repurchase program.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1) | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| July 1, 2009 through July 31, 2009 | 20,542,568 | $32.08 | 20,542,568 | $1,317,951,080 |
| August 1, 2009 through August 31, 2009 | 12,547,379 | 35.07 | 12,547,379 | 877,951,109 |
| September 1, 2009 through September 30, 2009 | 12,086,616 | 36.40 | 12,086,616 | 437,951,787 |

(1) On May 7, 2008, the Company’s Board of Directors authorized, effective May 21, 2008, a share repurchase program for up to $2.0 billion of outstanding common stock. The specific timing and amount of repurchases will vary based on market conditions and other factors. During the third quarter of 2009, the Company repurchased 45.2 million shares of common stock for $1.5 billion. The shares were placed into the Company’s treasury upon delivery. The stock repurchase program may be modified, extended or terminated by the Board of Directors at any time.

### Part II Item 6

### Exhibits

Filed Nov 5, 2009.
Source: SEC EDGAR, the filing index for accession 0001193125-09-225277. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
